X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (219144) 219144
Book Review (51765) 51765
Publication (26009) 26009
Book Chapter (1539) 1539
Newspaper Article (1131) 1131
Newsletter (812) 812
Book / eBook (665) 665
Conference Proceeding (644) 644
Dissertation (213) 213
Magazine Article (66) 66
Transcript (42) 42
Data Set (39) 39
Web Resource (37) 37
Reference (36) 36
Trade Publication Article (26) 26
Paper (14) 14
Government Document (5) 5
Streaming Video (4) 4
Presentation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (185468) 185468
humans (132733) 132733
animals (101471) 101471
proteins (56097) 56097
mice (48503) 48503
male (47275) 47275
cancer (44302) 44302
oncology (44284) 44284
apoptosis (41234) 41234
female (39839) 39839
kinases (36462) 36462
cell biology (35265) 35265
signal transduction (32849) 32849
expression (30619) 30619
gene expression (30420) 30420
research (29594) 29594
biochemistry & molecular biology (29096) 29096
pharmacology & pharmacy (27451) 27451
cell line, tumor (27315) 27315
phosphorylation (27088) 27088
analysis (26566) 26566
activation (24045) 24045
research article (22918) 22918
rats (22828) 22828
health aspects (22587) 22587
article (22222) 22222
medicine (21317) 21317
multidisciplinary sciences (20592) 20592
rodents (20551) 20551
physiological aspects (19709) 19709
genetic aspects (19134) 19134
inflammation (18938) 18938
tumors (18794) 18794
care and treatment (17811) 17811
mutation (17322) 17322
signal transduction - drug effects (16962) 16962
middle aged (16839) 16839
neurosciences (16790) 16790
science (16752) 16752
cells (16482) 16482
biology (15574) 15574
inhibition (15504) 15504
oxidative stress (15147) 15147
apoptosis - drug effects (15105) 15105
cells, cultured (14872) 14872
antineoplastic agents - therapeutic use (14220) 14220
cell proliferation (13719) 13719
metastasis (13662) 13662
adult (13588) 13588
medicine, research & experimental (13266) 13266
aged (13260) 13260
immunology (13172) 13172
protein kinase inhibitors - therapeutic use (13082) 13082
cell cycle (13059) 13059
chemotherapy (12952) 12952
development and progression (12761) 12761
disease models, animal (12743) 12743
studies (12395) 12395
gene-expression (12317) 12317
in-vitro (12131) 12131
antineoplastic agents - pharmacology (12130) 12130
protein (11692) 11692
physiology (11594) 11594
mice, inbred c57bl (11456) 11456
in-vivo (11290) 11290
genes (11221) 11221
cell proliferation - drug effects (11149) 11149
biochemistry (11134) 11134
breast cancer (10916) 10916
cell line (10908) 10908
nf-kappa-b (10661) 10661
cytokines (10645) 10645
growth (10412) 10412
medical research (10013) 10013
stem cells (9984) 9984
enzymes (9932) 9932
cancer therapies (9806) 9806
protein binding (9802) 9802
metabolism (9634) 9634
rats, sprague-dawley (9507) 9507
protein kinase inhibitors - pharmacology (9357) 9357
hematology (9236) 9236
cell growth (9186) 9186
review (9074) 9074
immunohistochemistry (9018) 9018
blotting, western (8931) 8931
dose-response relationship, drug (8920) 8920
protein kinases (8821) 8821
angiogenesis (8799) 8799
prognosis (8576) 8576
therapy (8465) 8465
proliferation (8365) 8365
medicine & public health (8281) 8281
abridged index medicus (8130) 8130
pathway (8031) 8031
signaling (8017) 8017
survival (8006) 8006
disease (7991) 7991
treatment outcome (7930) 7930
pathology (7917) 7917
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (381) 381
UofT at Mississauga - Stacks (55) 55
Collection Dvlpm't (Acquisitions) - Vendor file (51) 51
Online Resources - Online (48) 48
Collection Dvlpm't (Acquisitions) - Closed Orders (24) 24
UofT at Scarborough - Stacks (23) 23
Chemistry (A D Allen) - Stacks (19) 19
UTL at Downsview - May be requested (18) 18
Engineering & Comp. Sci. - Stacks (17) 17
Earth Sciences (Noranda) - Stacks (5) 5
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
UofT at Mississauga - Reference (3) 3
Gerstein Science - Circulation Desk (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Not Returned (1) 1
Gerstein Science - Reference (1) 1
Law (Bora Laskin) - Stacks (1) 1
Physics - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Missing (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (221298) 221298
French (347) 347
Japanese (323) 323
German (248) 248
Chinese (244) 244
Spanish (129) 129
Hungarian (40) 40
Czech (35) 35
Polish (29) 29
Russian (29) 29
Italian (24) 24
Dutch (16) 16
Danish (12) 12
Swedish (12) 12
Korean (7) 7
Norwegian (7) 7
Croatian (5) 5
Turkish (5) 5
Finnish (4) 4
Ukrainian (4) 4
Portuguese (3) 3
Hebrew (2) 2
Romanian (2) 2
Slovak (2) 2
Arabic (1) 1
Bulgarian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis | Index Medicus | Abridged Index Medicus
Journal Article
2009, 1. Aufl., Wiley Series in Drug Discovery and Development, ISBN 0470278293, Volume 10, xv, 510
A comprehensive resource on case studies of marketed kinase drugs and promising drug trialsSince the discovery of protein kinase activity in 1954, the field of... 
Protein Kinase Inhibitors | Inhibitors | drug therapy | pharmacology | metabolism | Antineoplastic agents | Protein kinases | Drug Discovery | Neoplasms | Therapeutic use | Protein kinases–Inhibitors–Therapeutic use | Medical | Pharmacology
Book
Drug Discovery Today, ISSN 1359-6446, 01/2016, Volume 21, Issue 1, pp. 5 - 10
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2012, Volume 7, Issue 12, pp. 1807 - 1814
Many patients with oncogene-driven non–small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression.... 
anaplastic lymphoma kinase gene arrangement non–small-cell lung cancer | EGFR-mutant non–small-cell lung cancer | Radiation therapy | Oligoprogressive disease | anaplastic lymphoma kinase gene arrangement non-small-cell lung cancer | EGFR-mutant non-small-cell lung cancer | PHASE-I/II TRIAL | ACQUIRED-RESISTANCE | BODY RADIATION-THERAPY | DOSE WEEKLY ERLOTINIB | BREAST-CANCER | LIVER METASTASES | SYNCHRONOUS BRAIN METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | LEPTOMENINGEAL METASTASES | RESPIRATORY SYSTEM | RECURRENT MALIGNANT GLIOMAS | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Pyrazoles - therapeutic use | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Catheter Ablation | Lung Neoplasms - pathology | Male | Young Adult | Brain Neoplasms - secondary | Aged, 80 and over | Adult | Female | Retrospective Studies | Brain Neoplasms - mortality | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Carcinoma, Non-Small-Cell Lung - therapy | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Gene Rearrangement | Brain Neoplasms - therapy | Aged | Neoplasm Staging | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase | Index Medicus | Abridged Index Medicus
Journal Article